XML 35 R22.htm IDEA: XBRL DOCUMENT v3.23.1
General (Tables)
3 Months Ended
Mar. 31, 2023
Prior Period Adjustment [Abstract]  
Schedule of error corrections and prior period adjustments The impact of the revision on the Company’s financial statements for the first quarter of 2022 is reflected in the following table:
 
    
As previously
report
    
Adjustment
    
As revised
 
Balance Sheet for March 31, 2022 (unaudited)
                          
Additional
paid-in
capital
   $ 434,305      $ 797      $ 435,102  
Accumulated deficit
     (429,179      (797      (429,976
Consolidated Statement of Operations and Comprehensive Loss for the three months March 31, 2022 (unaudited)
                          
Research and development expenses
     4,240        241        4,481  
Selling, general and administrative expenses
     3,648        556        4,204  
    
 
 
    
 
 
    
 
 
 
Total operating expenses
     7,888        797        8,685  
Operating loss
     (7,543      (797      (8,340
Net loss
     (8,203      (797      (9,000
Total other comprehensive loss
     (8,201      (797      (8,998
Basic and diluted loss per common share
     (1.00      (0.10      (1.10
Consolidated statement of Stockholders’ Equity (Deficit) for the three months ended March 31, 2022 (unaudited)
                          
Compensation expense for issuance of stock options
     1,474        797        2,271  
Net loss
     (8,203      (797      (9,000
Consolidated Statement of Cash Flows for the three months ended March 31, 2022 (unaudited)
                          
Net loss
     (8,203      (797      (9,000
Stock option compensation expense
     1,474        797        2,271  
Balance Sheet for June 30, 2022 (unaudited)
                          
Additional
paid-in
capital
     435,922        1,299        437,221  
Accumulated deficit
     (438,836      (1,299      (440,135